Weibin Liu is a Senior Analyst at KPCB China, where he focuses on life science investments and is a board observer at GenScript. Prior to joining KPCB in 2008, he worked at DFJ DragonFund supporting venture investments in life science and greentech. He has also worked in systems engineering at Novartis, investment management at Morgan Stanley, and molecular neuroscience research at the Zanvyl Krieger Mind/Brain Institute.

Weibin earned a B.S. with Honors in Molecular Biology and a M.S. in Biotechnology from Johns Hopkins University.

E-mail: weibinl@kpcb.com